Bryan Johnson Diagnosed With Autoimmune Gastritis and Plans to Try to Cure It
Biohacker Bryan Johnson reveals a May 2026 autoimmune gastritis diagnosis and outlines his intent to treat and potentially reverse the condition.
Summary
Bryan Johnson, known for his extreme anti-aging Blueprint protocol, announced he was diagnosed with autoimmune gastritis (AIG) in May 2026. AIG is a chronic inflammatory condition where the immune system attacks the stomach's parietal cells, leading to reduced acid production, impaired B12 absorption, and elevated risk of pernicious anemia and gastric cancer over time. Johnson frames the diagnosis not as a setback but as a challenge to be solved, stating his intention to attempt a cure. This is notable because AIG is generally considered a progressive, manageable but not reversible condition by conventional medicine. Johnson's case raises questions about whether aggressive lifestyle, dietary, and potentially immunomodulatory interventions could alter disease course. His willingness to share the diagnosis publicly offers a rare real-world window into how a highly optimized longevity protocol may still leave someone vulnerable to autoimmune disease.
Detailed Summary
Bryan Johnson, the entrepreneur behind the Blueprint longevity protocol who has invested heavily in biological age reversal, disclosed in this YouTube video that he was diagnosed with autoimmune gastritis in May 2026. The announcement is significant both personally and as a case study in the limits and possibilities of current longevity science.
Autoimmune gastritis is a condition in which the immune system mistakenly attacks the parietal cells of the stomach lining. These cells are responsible for producing hydrochloric acid and intrinsic factor, a protein essential for vitamin B12 absorption. Over time, AIG can lead to achlorhydria, B12 deficiency, pernicious anemia, and a meaningfully elevated risk of gastric neuroendocrine tumors and adenocarcinoma. It is typically considered a chronic, progressive condition with no established cure.
Johnson's diagnosis is striking because he follows one of the most rigorously documented anti-aging regimens in existence, including carefully controlled nutrition, extensive supplementation, sleep optimization, and regular biomarker monitoring. That he still developed an autoimmune condition underscores that even aggressive longevity protocols do not confer immunity to immune dysregulation.
The most provocative aspect of the video is Johnson's stated intention to attempt to cure AIG, not merely manage it. While conventional medicine focuses on B12 supplementation, proton pump inhibitor avoidance, and endoscopic surveillance, emerging research on immune modulation, gut microbiome restoration, and potentially regulatory T-cell therapies may offer unconventional approaches worth exploring.
For clinicians and longevity enthusiasts, this case is a reminder that autoimmune conditions represent a major frontier in aging and healthspan. Chronic inflammation and immune dysregulation are central drivers of biological aging, and conditions like AIG may accelerate systemic decline if unaddressed. Johnson's public documentation of his treatment journey could yield valuable observational data, even without a controlled trial design.
Key Findings
- Bryan Johnson was diagnosed with autoimmune gastritis in May 2026 despite following an intensive longevity protocol.
- AIG involves immune attack on stomach parietal cells, impairing acid production and B12 absorption over time.
- Johnson intends to attempt a cure rather than conventional disease management alone.
- AIG raises long-term cancer and pernicious anemia risk, making early detection and intervention critical.
- Even highly optimized longevity protocols do not appear to prevent autoimmune conditions.
Methodology
This is a personal disclosure video, not a clinical study. The content is based solely on Johnson's self-reported diagnosis and stated intentions, with no peer-reviewed data, controls, or outcome measurements presented.
Study Limitations
This summary is based on a brief video announcement with minimal clinical detail — no diagnostic workup, antibody titers, biopsy findings, or proposed treatment plan are disclosed. The summary is based on the abstract only. No peer-reviewed evidence is presented, and Johnson's stated goal of 'curing' AIG is aspirational and unvalidated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: